Evidence map›Paper›PMID 9445372›Full record

ArticleThe Biochemical journal1998

Identification of cardiac oxidoreductase(s) involved in the metabolism of the lipid peroxidation-derived aldehyde-4-hydroxynonenal.

S Srivastava, A Chandra, N H Ansari, S K Srivastava, A Bhatnagar

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. Glucose Metabolism in Cardiac Hypertrophy and Heart Failure.Journal of the American Heart Association · 2019
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. The role of Cys-298 in aldose reductase function.The Journal of biological chemistry · 2011
    Article
  12. Article
  13. Review
  14. Article
  15. Arsenic and cardiovascular disease.Toxicological sciences : an official journal of the Society of Toxicology · 2009
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Aldose reductase-catalyzed reduction of aldehyde phospholipids.The Journal of biological chemistry · 2004
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

S SrivastavaDepartment of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77555-1067, USA.
A Chandra
N H Ansari
S K Srivastava
A Bhatnagar
The University of Texas Medical Branch at Galveston · US

Funding

TOXICITY OF 4-HYDROXYALKENALS IN HEARTR01HL055477 · NHLBI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI BHATNAGAR, ARUNI · 1997 to 2015
$4.4M
Role of Aldose Reductase in Diabetic ComplicationsR37DK036118 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SRIVASTAVA, SATISH K · 2003 to 2013
$4.1M
ALDOSE REDUCTASE AND DIABETIC COMPLICATIONSR01DK036118 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SRIVASTAVA, SATISH K · 1987 to 2002
$626k
NHLBI NIH HHS HL55477NIDDK NIH HHS DK 36118
6 · The paper itself

Abstract

The aim of this study was to identify the cardiac oxidoreductases involved in the metabolism of 4-hydroxy-2-trans-nonenal (HNE), an alpha,beta unsaturated aldehyde generated during the peroxidation of omega-6 polyunsaturated fatty acids. In homogenates of bovine, human and rat ventricles the primary pyridine coenzyme-linked metabolism of HNE was associated with NADPH oxidation. The NADPH-dependent enzyme catalysing HNE reduction was purified to homogeneity from bovine heart. The purified enzyme displayed kinetic and immunological properties identical with the polyol pathway enzyme aldose reductase (AR), and catalysed the reduction of HNE to its alcohol 1,4-dihydroxynonene (DHN), with a Km of 7+/-2 microM. In the presence of NADP the enzyme did not catalyse the oxidation of DHN. During catalysis, HNE did not cause inactivation of AR. Nevertheless when the apoenzyme was incubated with HNE a dissociable complex was formed between the enzyme and HNE, followed by irreversible loss of activity. Inactivation of the enzyme by HNE was prevented by NADP. Partial modification of the enzyme with HNE led to a 17-fold increase in the KHNEm and Kglyceraldehydem, and the HNE-modified enzyme had a 500-fold higher IC50 for sorbinil than for the reduced enzyme, whereas the IC50 for tolrestat increased 25-fold. Incubation of the enzyme with radiolabelled HNE resulted in the incorporation of 2 mol of the aldehyde per mol of the enzyme. Sequence analysis of the radiolabelled peptides revealed modification of Cys-298 and Cys-187. The amino acid sequence of the HNE-modified peptides confirmed that the HNE-reducing cardiac enzyme is AR and not a related protein such as the fibroblast-growth-factor-regulated protein FR-1 or the mouse vas deferens protein MVDP. These results indicate that AR represents the only major oxidoreductase in the heart capable of utilizing HNE. The high affinity of the enzyme for HNE, the lack of inactivation during catalysis, and the lack of significant alcohol dehydrogenase activity of the protein suggests that AR-mediated catalysis of HNE is unlikely to be limited by substrate/product inhibition. Thus AR might constitute an antioxidative enzyme involved in myocardial protection against endogenous and exogenous cytotoxic aldehydes and against oxidative stress.

Indexed as

Lipid PeroxidationAldehyde ReductaseAldehydesAmino AcidsAmino Acid SequenceAnimalsCattleEnzyme ActivationHumansKineticsMaleMolecular Sequence DataMyocardiumRatsRats, Sprague-DawleySubcellular Fractions4-hydroxy-2-nonenalAldehyde ReductaseAldehydesAmino Acids

Identifiers

PMID9445372
PMCPMC1219066
OpenAlexW2335890598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.